Telehealth company Hims & Hers is testing an artificial intelligence and machine learning clinical decision support feature that could suggest treatments for some mental health conditions.
The company said its MedMatch technology can recommend clinicians prescribe certain medications and doses. With the development, Hims & Hers joins a growing number of digital health companies attempting to differentiate their offerings by turning to clinical decision support technology.
In beta testing over the past month, about 75% of clinicians have included prescription treatment and diagnosis information from the clinical decision support technology in evaluation and treatment, said founder and CEO Andrew Dudum.
The program will recommend a treatment and prescription inside of the physician's workflow based on information in the electronic health record.
“A really powerful benefit of digital health platforms like ours is they can actually just standardize the quality of care much better than a traditional brick and mortar,” Dudum said. “What it really helps do is meaningfully improve the quality and consistency of care. [It can] reduce the standard variation of care that an individual might get.”
Dudum said the company has plans to roll out the technology to other clinical areas by the end of the year. “We think this is going to be really important across all of the categories that we're currently operating, as well as in some of the newer categories like weight loss," he said.
The company plans to join a growing number of digital health companies offering weight loss programs by the end of the year.
Dudum said the company began working on MedMatch about a year ago. He did not rule out licensing the software to health systems and other brick-and-mortar providers, but said the company did not have immediate plans to do so.
On Monday, Hims & Hers reported a third-quarter net loss of $7.6 million, or 4 cents per share, compared with a net loss of $18.8 million, or 9 cents per share, in the year-ago period. Quarterly revenues increased 57%, to $226.7 million.